<code id='C835745595'></code><style id='C835745595'></style>
    • <acronym id='C835745595'></acronym>
      <center id='C835745595'><center id='C835745595'><tfoot id='C835745595'></tfoot></center><abbr id='C835745595'><dir id='C835745595'><tfoot id='C835745595'></tfoot><noframes id='C835745595'>

    • <optgroup id='C835745595'><strike id='C835745595'><sup id='C835745595'></sup></strike><code id='C835745595'></code></optgroup>
        1. <b id='C835745595'><label id='C835745595'><select id='C835745595'><dt id='C835745595'><span id='C835745595'></span></dt></select></label></b><u id='C835745595'></u>
          <i id='C835745595'><strike id='C835745595'><tt id='C835745595'><pre id='C835745595'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:9659
          People in business and medical wardrobe in a table discussion — coverage from STAT
          Adobe

          R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

          Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

          advertisement

          In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Readout Newsletter: Bristol, Sangamo, Gilead, and more
          Readout Newsletter: Bristol, Sangamo, Gilead, and more

          EricRisberg/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsl

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          Fed up with FDA, ALS advocates consider a take

          Ademonstrationmarkingthe10thanniversaryoftheformationACTUP,inNewYork.MarkLennihan/APWASHINGTON—NextW